| SEC | Form | 4 |
|-----|------|---|
|-----|------|---|

## FORM 4

Check this box if no longer subject to

Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

> Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

|   | Check this box to indicate that a             |
|---|---|
|   | transaction was made pursuant to a            |
| - | contract, instruction or written plan for the |
|   | purchase or sale of equity securities of the  |
| - | issuer that is intended to satisfy the        |

affirmative defense conditions of Rule

| (City)  | (State)  | (Zip)   | -Derivative Securities Acquired, Disposed of, or Beneficia                                   |  |  |  |  |  |
|---|--|---------|--|--|--|--|--|--|
| (Street)<br>PASADENA  | СА   | 91101   |  | X Form filed by One Reporting Person<br>Form filed by More than One Reporting Person   |  |  |  |  |
| 1000 E. COLOKADO BEVD., SOITE 180                           |  |         | 4. If Amendment, Date of Original Filed (Month/Day/Year)                                     | 6. Individual or Joint/Group Filing (Check Applicable Line)  |  |  |  |  |
| (Last) (First) (Middle)<br>680 E. COLORADO BLVD., SUITE 180 |  | · · · · | 3. Date of Earliest Transaction (Month/Day/Year)<br>09/30/2024                               | below) below)  |  |  |  |  |
|   | . Name and Address of Reporting Person <sup>*</sup> Brown Regina |         | 2. Issuer Name and Ticker or Trading Symbol <u>LIXTE BIOTECHNOLOGY HOLDINGS, INC.</u> [LIXT] | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br>X Director 10% Owner<br>Officer (give title Other (specify |  |  |  |  |
| 10b5-1(c). See In   | nstruction 10.   |         |  | 1  |  |  |  |  |

| ······································ | 2. Transaction<br>Date<br>(Month/Day/Year) | <br>3.<br>Transac<br>Code (Ir<br>8) | Instr. |        | (Instr. 3, 4 and 5) |       | Securities<br>Beneficially Owned<br>Following Reported | (Instr. 4) | 7. Nature of<br>Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|--|--|-------------------------------------|--------|--------|---------------------|-------|--|------------|---|
|  |  | Code                                | v      | Amount | (A) or<br>(D)       | Price | Transaction(s)<br>(Instr. 3 and 4)                     |            | (IIISU. 4)  |

 
 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security (Instr.<br>3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security |            | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transaction<br>Code (Instr.<br>8) |   | 5. Number of<br>Derivative<br>Securities<br>Acquired (A)<br>or Disposed<br>of (D) (Instr. 3,<br>4 and 5) |     | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount of<br>Securities Underlying<br>Derivative Security (Instr.<br>3 and 4) |                                     | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---|---|------------|---|---|---|--|-----|--|--------------------|--|-------------------------------------|---|--|--|--|
|   |   |            |   | Code                                    | v | (A)  | (D) | Date<br>Exercisable  | Expiration<br>Date | Title  | Amount<br>or<br>Number<br>of Shares |   | Transaction(s)<br>(Instr. 4)   |  |  |
| Options to<br>Purchase<br>Common Stock              | \$1.3   | 09/30/2024 |   | A                                       |   | 6,269  |     | 09/30/2024   | 09/30/2029         | Common   | 6,269                               | \$0 <sup>(1)</sup>                                  | 6,269  | D  |  |
| Options to<br>Purchase<br>Common Stock              | \$2.37  |            |   |   |   |  |     | 06/30/2024   | 06/30/2029         | Common   | 10,000                              |   | 10,000   | D  |  |
| Options to<br>Purchase<br>Common Stock              | \$2.37  |            |   |   |   |  |     | 06/30/2024   | 06/30/2029         | Common   | 4,904                               |   | 4,904  | D  |  |
| Options to<br>Purchase<br>Common Stock              | \$5.88  |            |   |   |   |  |     | 06/30/2023   | 06/30/2028         | Common   | 10,000                              |   | 10,000   | D  |  |
| Options to<br>Purchase<br>Common Stock              | \$7.45  |            |   |   |   |  |     | 06/30/2022   | 06/30/2027         | Common   | 10,000                              |   | 10,000   | D  |  |
| Options to<br>Purchase<br>Common Stock              | \$30.3  |            |   |   |   |  |     | 06/30/2021   | 06/30/2026         | Common   | 10,000                              |   | 10,000   | D  |  |
| Options to<br>Purchase<br>Common Stock              | \$28  |            |   |   |   |  |     | 05/11/2021   | 05/11/2026         | Common   | 25,000                              |   | 25,000   | D  |  |

## Explanation of Responses:

1. Effective September 30, 2024, the reporting person was granted stock options to purchase an aggregate of 6,296 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

/s/ Regina Brown

\*\* Signature of Reporting Person

<u>10/28/2024</u> Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.